ArticleImmunotherapy2016
Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
Article in Immunotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.The Journal of clinical investigation · 2022Trial
- Unconventional guardians of the brain: MAIT cells as emerging players in glioblastoma immunity.Frontiers in immunology · 2026Review
- The gut microbiota protein BOC1 exhibits immune checkpoint inhibitor-like activity by inhibiting myeloid-derived suppressor cell differentiation.Frontiers in immunology · 2025Article
- Article
- Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.Molecular therapy oncolytics · 2023Article
- Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade.Frontiers in oncology · 2023Review
- CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors.Expert opinion on investigational drugs · 2022Article
- Article
- CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.Frontiers in pharmacology · 2021Review
- CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment.Cancer immunology, immunotherapy : CII · 2020Article
- Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group.Scientific reports · 2020Article
- CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.Advances in experimental medicine and biology · 2020Review
- Pre-transplant CD200 and CD200R1 concentrations are associated with post-transplant events in kidney transplant recipients.Medicine · 2019Article
- Article
- Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Cancer management and research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
There are over 400 ongoing clinical trials using tumor-derived vaccines. This approach is especially attractive for many types of brain tumors, including glioblastoma, yet so far the clinical response is highly variable. One contributor to poor response is CD200, which acts as a checkpoint blockade, inducing immune tolerance. We demonstrate that, in response to vaccination, glioma-derived CD200 suppresses the anti-tumor immune response. In contrast, a CD200 peptide inhibitor that activates antigen-presenting cells overcomes immune tolerance. The addition of the CD200 inhibitor significantly increased leukocyte infiltration into the vaccine site, cytokine and chemokine production, and cytolytic activity. Our data therefore suggest that CD200 suppresses the immune system's response to vaccines, and that blocking CD200 could improve the efficacy of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.